Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on July 7, 2025, and filed on July 8, 2025. The Company, a foreign private issuer, executed a share repurchase through its corporate stockbroker, Merrill Lynch International, as part of an existing buyback programme established via a non-discretionary agreement on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific block of share purchases rather than comprehensive financial statements. Key metrics for the transaction on July 7, 2025, include:
- Shares Purchased: 485,199 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,387.50 GBp; highest price paid was 1,404.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,395.87 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON). No purchases were made on CBOE Europe (CHIX or BATE).
- Treasury Share Holdings: Following this purchase, the Company holds 228,598,075 ordinary shares in treasury.
- Shares in Issue: 4,086,783,775 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.59% of the total voting rights.
Material Changes and Programme Progress
Since the commencement of the current buyback agreement on June 4, 2025, the Company has purchased an aggregate of 10,463,692 ordinary shares. The July 7 transaction represents a continuation of this programme. The filing does not provide comparative financial data (e.g., revenue, profit, or cash flow) for the period, as it is a transaction-specific report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the Company's 2024 Annual Report on Form 20-F and Q1 2025 Results. The purchased shares are held as Treasury shares and do not carry voting rights.
Important Facts for Investor Verification
- Verify the total remaining authorization under the buyback programme announced on June 4, 2025, to assess the remaining capacity for share repurchases.
- Confirm the impact of the 5.59% treasury share holding on earnings per share (EPS) calculations and voting thresholds.
- Review the Company's 2024 Form 20-F and Q1 2025 Results for the risk factors referenced in the cautionary statement.
- Note that the filing does not disclose the total cash outflow for the entire buyback programme to date, only the specific transaction details for July 7.